News and Announcements
Van Leeuwenhoeck Institute initiates Research Coverage with OncoSil
- Published October 02, 2015 4:41PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st October 2015, ASX Announcement
OncoSil Medical Limited (OncoSil Medical, the Company) is pleased to announce that international life sciences research group, Van Leeuwenhoeck Institute, has initiated analyst research coverage on the Company.
The Van Leeuwenhoeck Institute research report is available via the OncoSil Medical company website;
OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSil localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSil for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.
To read the full announcement, please click here.